Paul Twarog Email & Phone Number

Cleveland, Ohio, United States

Cleveland, Ohio, United States

President’s award winner

Raleigh-Durham, North Carolina Area

Served as hospital sales representative launching a new anti-fungal (Tolsura) for inpatient and outpatient treatment. Worked with infectious disease specialties and critical care, including transplant, HIV, pulmonary and internal medicine. Currently covering Northern Ohio and the lower peninsula of Michigan.• Achieved the first hospital formulary addition in the country in 4 months (University Hospitals Case Medical Center). • Achieved the second hospital formulary addition in the country in 5 months at the company’s number one antifungal targeted account (The Cleveland Clinic).• Won the initial six month Tolsura script launch award.• Developed and maintained relationships with key opinion leaders.

Cleveland/Akron, Ohio Area

Served as hospital sales representative focused on non-opioid pain management (Ofirmev, IV Acetaminophen) covering large academic and community hospitals and outpatient surgical centers in Northeast Ohio. Worked with surgical specialties and critical care, including orthopedics, cardio-thoracic, colorectal, gynecology, bariatric, internal medicine, and pharmacy. • Attained 115% of goal for first half of 2018.• Won multiple Impact Awards for leadership, collaboration, and cultural hallmarks from management and peers.• Finished 2017 at 100% to goal.• Won 2016 Fourth Quarter Top-Ten Sales Growth Award and 2016 Cultural Hallmark Award (Ohio District).• Selected as field sales trainer for Great Lakes district (2016-2018).• Chosen for Mallinckrodt Leadership Training Program (completed in May 2017).• Developed and maintained relationships with key opinion leaders and speakers.

Cleveland/Akron, Ohio Area

Operated as specialized hospital account manager focused on respiratory, critical care, and oncology/hematology. Marketed respiratory product line, including Advair, Breo, and Anoro. Sold blood products for orthopedic surgical procedures and oncology products for ovarian and lung cancers as well as Non-Hodgkin’s Lymphoma. Managed Cleveland Clinic, MetroHealth Medical Center, and University Hospitals System. • Converted University Hospitals System in Cleveland, Ohio, including the 11 UH regional hospitals, from generic respiratory therapy to Advair. • Developed business plan consisting of technical, contractual, and training discussions with pulmonology, internal medicine, respiratory therapy, nursing, and pharmacy. • Won 2009 Ruby Elite Award for Top 15% in country.• Launched Breo and Anoro in respiratory marketplace.• Appointed field sales trainer for Ohio/West Virginia region. • Ranked in top ten in sales growth for Arixtra (anti-thrombotic for surgical procedures).• Launched Bexxar (radioimmunotherapy for Non-Hodgkin’s Lymphoma) in Cleveland area, including first procedures in Ohio/West Virginia region. Led region in sales. • Served as national trainer at national meetings and mentored new hires.

Sales specialist on neurosurgical / oncology team focused on the Gliadel® Wafer (Polifeprosan 20 with Carmustine Implant) indicated for Glioblastoma Multiforme.• Top 3 in sales for the six months while with Guilford.

Member of Oncology sales team created to bring a new and unique radiotherapy to the Non-Hodgkin’s Lymphoma marketplace (Bexxar). Product approval was delayed beyond employment.n• Led the Midwest Region in Metastron, Strontium-89 (Radio therapy for Prostrate Cancer), percent sales to goal for the first six months of sales, July-December 2001. • Led the Midwest Region at 115% sales to goal for first three months of 2002.• Developed Launch Strategy for new therapeutic class of drug, Bexxar, for the Northern Ohio and Michigan territories creating easier implementation of product upon launch. Strategy included developing technical relationships with medical professionals in Hematology/Oncology, Radiation Oncology, and Nuclear Medicine. Strategy demonstrated by successful launch with GlaxoSmithKline. • Appointed Regional Trainer for Metastron and Bexxar due to clinical expertise.